wrap lower est light humira
guidanc focu shift launch
lower est dampen top-line outlook
result in-lin total revenu ep forecast product
sale miss weaker expect sale guidanc y/i vs prior
lead us lower overal forecast out-year sale forecast
major forecast reduct come global humira although
also forecast generic androgel follow launch gener
previous disclos settlement launch date forecast lower opex
negat ep impact sale reduct less optimist
abbv abil flex cost structur compani need fund four
import new product launch thu trim ep period new po
reflect aforement revis estim lower pe multipl
vs prior well slightli lower termin growth rate vs
reiter neutral rate given limit upsid share rel po
unfavor macro backdrop compani high singl product concentr risk
takeaway call
takeaway us humira management guid y/i growth expect growth
underpin volum plu one-tim list price increas taken begin
year humira script grew y/i base growth trend believ
half growth come volum management confirm would take second
list price increas price consist industry-trend limit list
price increas mid-sd vs high sd histor ex-u humira major
ou busi face biosimilar exposur europ remaind market
expect face biosimilar competit management expect y/i
eros vs declin call assum increment eros may
occur given price dynam settl certain eu countri
commentari management clarifi interest signific merger-typ deal
separ comment deal rang like pharmacycl within
compani capac
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
research-bas global pharmaceut
busi spun abbott
develop market drug area
immunolog virolog oncolog
rate neutral growth new
product launch balanc competit headwind
 see limit upsid consensu risa sale
forecast use limit psoriasi
indic next sever year
numer novel biolog competitor similar
valu proposit stock impact venclexta
upsid limit due partnership econom
orilissa upsid possibl would repres
fraction pend loe exposur
price object po base blend valuat risk-adjust dcf
price-to-earnings multipl non-gaap ep estim base ep growth
profil assum wacc termin growth rate believ
dcf assumpt reason minim contribut pipelin
valid late-stag clinic studi histor trade
discount peer price-to-earnings owe humira biosimilar risk
downsid risk earlier-than-anticip launch humira biosimilar us
clinic pipelin failur
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
